CD8A and cancer: Interferon levels may serve as biomarkers for immunotherapy response across various cancer types[88-90], with work by Boukhaled et al. demonstrating that pre-treatment resistance to IFN-I in peripheral blood CD4+ and CD8+ T cells positively correlates with long-term survival following PD-1 inhibitor therapy[91] [Figure 3].